Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review
Author:
Publisher
Elsevier BV
Subject
Urology,Oncology
Reference24 articles.
1. New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview;Motzer;Oncologist,2011
2. Cancer statistics, 2019;Siegel;CA Cancer J Clin,2019
3. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma;Mejean;N Engl J Med,2018
4. Kidney cancer: opportunity for disease specific targeted therapy;Linehan;Urol Oncol,2008
5. Everolimus versus sunitinib for patients with metastatic non–clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial;Armstrong;Lancet Oncol,2016
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena;Cancer Drug Resistance;2023-09-20
2. Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney – how to achieve a safe and radical resection? a case report and review of the literature;Frontiers in Oncology;2023-07-14
3. The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer;Urologic Clinics of North America;2023-05
4. Neoadjuvant Therapy in Locally Advanced Renal Cell Carcinoma;Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma;2023
5. Ipsilateral synchronous papillary and clear renal cell carcinoma: A case report and review of literature;World Journal of Clinical Cases;2022-06-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3